Research Article
GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF-κB Signaling Pathways
Figure 6
Histological analysis of the therapeutic effect of GLX on CFA-induced TMJ inflammation in rats. (a) Representative images of H&E, S&F, and immunofluorescence staining of NOX4 on day 7 after treatment from each group. (b) Representative images of H&E, S&F, and immunofluorescence staining of NOX4 on day 14 after treatment from each group. (c) Quantification of the synovitis score ( independent animals). (d) Quantification of the OARSI score ( independent animals). (e) Quantitative analysis of the relative NOX4 fluorescence (% of saline group) ( independent animals). The data represent the from three independent replicates (one-way ANOVA with Tukey’s post hoc tests). , compared with the saline group; #, ## compared with the CFA group.